DSpace Repository

Molecular targets of apigenin in colorectal cancer cells: Involvement of p21, NAG-1 and p53

Show simple item record

dc.contributor.author Zhong Y.
dc.contributor.author Krisanapun C.
dc.contributor.author Lee S.-H.
dc.contributor.author Nualsanit T.
dc.contributor.author Sams C.
dc.contributor.author Peungvicha P.
dc.contributor.author Baek S.J.
dc.date.accessioned 2021-04-05T03:36:14Z
dc.date.available 2021-04-05T03:36:14Z
dc.date.issued 2010
dc.identifier.issn 9598049
dc.identifier.other 2-s2.0-78649635941
dc.identifier.uri https://ir.swu.ac.th/jspui/handle/123456789/14645
dc.identifier.uri https://www.scopus.com/inward/record.uri?eid=2-s2.0-78649635941&doi=10.1016%2fj.ejca.2010.07.007&partnerID=40&md5=fbc768649884fdf97767d863c19e33a5
dc.description.abstract Persuasive epidemiological and experimental evidence suggests that dietary flavonoids have anti-cancer activity. Since conventional therapeutic and surgical approaches have not been able to fully control the incidence and outcome of most cancer types, including colorectal neoplasia, there is an urgent need to develop alternative approaches for the management of cancer. We sought to develop the best flavonoids for the inhibition of cell growth, and apigenin (flavone) proved to be the most promising compound in colorectal cancer cell growth arrest. Subsequently, we found that pro-apoptotic proteins (NAG-1 and p53) and cell cycle inhibitor (p21) were induced in the presence of apigenin, and kinase pathways, including PKCδ and ataxia telangiectasia mutated (ATM), play an important role in activating these proteins. The data generated by in vitro experiments were confirmed in an animal study using APC MIN+ mice. Apigenin is able to reduce polyp numbers, accompanied by increasing p53 activation through phosphorylation in animal models. Our data suggest apparent beneficial effects of apigenin on colon cancer. © 2010 Elsevier Ltd. All rights reserved.
dc.subject antineoplastic agent
dc.subject apigenin
dc.subject ATM protein
dc.subject protein
dc.subject protein kinase C gamma
dc.subject protein nag 1
dc.subject protein p21
dc.subject protein p53
dc.subject unclassified drug
dc.subject animal experiment
dc.subject animal model
dc.subject antineoplastic activity
dc.subject article
dc.subject cancer cell
dc.subject colorectal cancer
dc.subject controlled study
dc.subject enzyme activation
dc.subject human
dc.subject human cell
dc.subject in vitro study
dc.subject liquid chromatography
dc.subject mouse
dc.subject nonhuman
dc.subject priority journal
dc.subject protein expression
dc.subject protein phosphorylation
dc.subject reverse transcription polymerase chain reaction
dc.subject signal transduction
dc.subject transient transfection
dc.subject Western blotting
dc.subject Animals
dc.subject Antineoplastic Agents
dc.subject Apigenin
dc.subject Apoptosis
dc.subject Cell Proliferation
dc.subject Colorectal Neoplasms
dc.subject Cyclin-Dependent Kinase Inhibitor p21
dc.subject Enzyme Inhibitors
dc.subject Growth Differentiation Factor 15
dc.subject Humans
dc.subject Mice
dc.subject Phosphorylation
dc.subject Phosphotransferases
dc.subject Tumor Cells, Cultured
dc.subject Tumor Suppressor Protein p53
dc.title Molecular targets of apigenin in colorectal cancer cells: Involvement of p21, NAG-1 and p53
dc.type Article
dc.rights.holder Scopus
dc.identifier.bibliograpycitation European Journal of Cancer. Vol 46, No.18 (2010), p.3365-3374
dc.identifier.doi 10.1016/j.ejca.2010.07.007


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics